RxDoctor Payments Data

Eunice Gbenoba

Adult Health · Houston, TXNPI 1336173327

Payments from drug & device makers

$895in general payments, 2019–2025

Across 45 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$207
  • Novo Nordisk$184
  • Lilly USA, LLC$114
  • Medtronic$58
  • Xeris Pharmaceuticals, Inc.$49
  • Corcept Therapeutics$44
  • plus $239 from 11 others

What the payments were for

  • Food & beverage$895100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$895 in reported general payments places this provider in the 65th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$58,370
Medicare patients
201
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$168,263
JardianceEmpagliflozin71$81,350
MounjaroTirzepatide37$56,815
TrulicityDulaglutide30$44,768
FarxigaDapagliflozin Propanediol18$31,589
Tresiba Flextouch U-200Insulin Degludec29$30,667
TradjentaLinagliptin23$27,393
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$15,812
RybelsusSemaglutide16$15,031
Fiasp FlextouchInsulin Aspart (Niacinamide)13$12,044
Humalog Kwikpen U-100Insulin Lispro43$10,050
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro23$9,990
Insulin Lispro Kwikpen U-100Insulin Lispro38$9,174
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,508
VascepaIcosapent Ethyl13$6,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$184$183,294148 claims
Lilly USA, LLCMounjaro, Trulicity$114$101,58367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 933 adult health providers in Texas.

Other adult health in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →